TY - JOUR
T1 - Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
AU - Eisen, Andrea
AU - Lubinski, Jan
AU - Gronwald, Jacek
AU - Moller, Pal
AU - Lynch, Henry T.
AU - Klijn, Jan
AU - Kim-Sing, Charmaine
AU - Neuhausen, Susan L.
AU - Gilbert, Lucy
AU - Ghadirian, Parviz
AU - Manoukian, Siranoush
AU - Rennert, Gad
AU - Friedman, Eitan
AU - Isaacs, Claudine
AU - Rosen, Eliot
AU - Rosen, Barry
AU - Daly, Mary
AU - Sun, Ping
AU - Narod, Steven A.
AU - Olopade, Olufunmilayo
AU - Cummings, Shelly
AU - Tung, Nadine
AU - Couch, Fergus
AU - Foulkes, William D.
AU - Domchek, Susan
AU - Stoppa-Lyonnet, Dominique
AU - Gershoni-Baruch, Ruth
AU - Horsman, David
AU - Wagner, Teresa
AU - Saal, Howard
AU - Warner, Ellen
AU - Meschino, Wendy
AU - Offit, Kenneth
AU - Trivedi, Amber
AU - Robson, Mark
AU - Osborne, Michael
AU - Gilchrist, Dawna
AU - Eng, Charis
AU - Weitzel, Jeffrey
AU - McKinnon, Wendy
AU - Wood, Marie
AU - Maugard, Christine
AU - Pasini, Barbara
AU - Ainsworth, Peter
AU - Sweet, Kevin
AU - Pasche, Boris
AU - Fallen, Taya
AU - Karlan, Beth
AU - Kurz, Raluca N.
AU - Armel, Susan
AU - Tulman, Anna
AU - Lemire, Edmond
AU - Mclennan, Jane
AU - Evans, Gareth
AU - Byrski, Tomas
AU - Huzarski, Tomas
AU - Shulman, Lee
N1 - Funding Information:
Department of Medical Genetics, The National Hospital, Oslo, Norway (PM); Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE (HTL); Daniel Van den Hoed Cancer Center, Rotterdam, The Netherlands (JK); BC Cancer Agency, Vancouver, BC, Canada (CKS); Department of Epidemiology, University of California, Irvine, CA (SLN); Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada (LG); Epidemiology Research Unit, Research Centre, Centre Hospitalier de l ’ Universitaire Montréal, CHUM Hôtel Dieu, Montreal, Quebec, Canada (PG); Unit of Medical Genetics, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy (SM); CHS National Cancer Control Center, Carmel Medical Center, Haifa, Israel (GR); Oncogenetics Unit, Chaim Sheba Medical Center, Tel-Hashomer, Israel (EF); Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC (CI, ER); University Health Network, Toronto, Ontario, Canada (BR); Fox Chase Cancer Center, Philadelphia, PA (MD); Women’s College Research Institute, Women’s College Hospital, University of Toronto, Ontario, Canada (PS, SAN) .
PY - 2008/10
Y1 - 2008/10
N2 - Background: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. Methods: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. Results: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95% CI = 0.35 to 0.96; P =. 03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 0.98; P =. 04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95% CI = 0.34 to 1.27; P =. 21). Conclusion: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.
AB - Background: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. Methods: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. Results: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95% CI = 0.35 to 0.96; P =. 03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 0.98; P =. 04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95% CI = 0.34 to 1.27; P =. 21). Conclusion: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.
UR - http://www.scopus.com/inward/record.url?scp=53249097506&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53249097506&partnerID=8YFLogxK
U2 - 10.1093/jnci/djn313
DO - 10.1093/jnci/djn313
M3 - Article
C2 - 18812548
AN - SCOPUS:53249097506
SN - 0027-8874
VL - 100
SP - 1361
EP - 1367
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 19
ER -